A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected.
A method to inhibit small extracellular vesicles (sEVs) released by tumor cells to enhance lipid nanoparticle (LNP) accumulation in tumors.
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis.
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications.
[%brief%]
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity).
A tissue-selective, biocompatible contrast agent enables the visual identification of tumors and tumor margins during procedures
A DNA vaccine targeting tumor endothelial marker 1 (TEM1) that allows to prevent and delay tumor progression without adverse effect on physiologic angiogenesis
Targeting retinoic acid (RA) synthesizing enzymes or RA receptors with small molecules boosts the immune system towards a tumor rejection response